Intracranial Aneurysm, Ruptured Aneurysm
Conditions
Keywords
wide neck, intradural aneurysm
Brief summary
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
Detailed description
The ELEVATE study is a prospective, multi-center, single-arm trial of the Pipeline™ Shield Device for the treatment of adults with acutely ruptured intracranial aneurysms. The primary objective of the ELEVATE study is to assess the safety and effectiveness of treatment with the Pipeline™ Shield Device of acutely ruptured intracranial aneurysms that are not amenable for clipping and coiling.
Interventions
The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
Sponsors
Medtronic Neurovascular Clinical Affairs
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subject has a previously untreated, wide neck, side-wall, intradural aneurysm that is deemed unfavorable for both surgical clipping and endovascular coiling, as confirmed on DSA. 2. Subject has a ruptured intracranial aneurysm with vessel diameter suitable for treatment with the study device. 3. Subject is ≥ 22 and ≤ 80 years of age. 4. Subject has an acutely ruptured aneurysm with Hunt and Hess Scale 1, 2 or 3. 5. Subject or subject's Legally Authorized Representative (LAR) has provided written informed consent.
Exclusion criteria
1. Subject's vessel characteristics preclude safe endovascular access to the aneurysm to treat with the Pipeline™ Shield Device. 2. Subject has aneurysm vessel characteristics that would preclude the device from fully conforming to the parent vessel to reduce any risk of embolic complications, retreatment, or device movement. 3. Subject has true bifurcation or aneurysms with vessels that cannot be separated from the fundus with placement of the study device. 4. Subject with intraparenchymal hemorrhage. 5. Subject is unable to undergo nasogastric/orogastric tube placement prior to device placement. 6. Subject has a pre-morbid mRS \>2. 7. Subject requires treatment of another aneurysm (with another treatment modality) within the affected territory of the target aneurysm. 8. Subject has a target ruptured aneurysm that is thought to be mycotic, including those caused by left atrial myxoma, or subject has an active systemic bacterial infection. 9. Subject with a requirement for continuous anti-coagulation. 10. Subject has a malignant brain tumor or vascular malformation (e.g. arteriovenous malformation). 11. Subject's target ruptured aneurysm has not been determined by the treating physician to be the source of SAH. 12. Subject with known allergy to platinum or cobalt chromium alloy (including the major elements platinum, cobalt, chromium, nickel or molybdenum). 13. Subject has a known hypersensitivity to ticagrelor or aspirin. 14. Subject is unable to undergo DSA or DSA is determined unsuitable by the treating physician. 15. Subject has a serious or life-threatening comorbidity that could confound study results. 16. Subject is at high risk of noncompliance per treating physician due to reasons including but not limited to a history of substance abuse. 17. Subject is unable to complete scheduled follow-up assessments due to comorbidities, geographical limitations, or a life expectancy of less than 24 months. 18. Subject is pregnant, or breastfeeding at the time of admission or plans to become pregnant during their participation in the study. 19. Subject is participating in another clinical study at the time of enrollment. 20. Presumed septic embolus, or suspicion of microbial superinfection. 21. Subject with a known COVID-19 viral infection, confirmed by testing. 22. Subject in whom a pre-existing stent is in place in the parent artery at target aneurysm location.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of neurological death or disabling stroke post-procedure. | at 365-day | Disabling stroke is defined as any post-procedural ischemic or hemorrhagic event that results in poor functional outcome (i.e. mRS ≥ 3 points) assessed at 90 days post stroke event. |
| Incidence of complete angiographic occlusion without significant stenosis, and no rebleeding or retreatment of the target aneurysm | at 365-day | Occlusion is measured by the Raymond Roy Scale. Significant stenosis is classified as ≤ 50%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of rebleed of target aneurysm | through 180-day and 365-day post procedure | — |
| Incidence of neurological hemorrhagic serious adverse events | through 180-day and 365-day post procedure | — |
| Incidence of ipsilateral major stroke or neurological death post-procedure after 30 days | through 180-day and 365-day post procedure | — |
| Incidence of any ipsilateral stroke post-procedure after 30 days | through 180-day and 365-day post procedure | — |
| Good clinical outcome (modified Rankin Scale (mRS) 0-2) | at 30-day, 180-day and 365-day post procedure | Scale for measuring general neurologic function: 0- No symptoms at all 1. No significant disability despite symptoms; able to carry out all usual duties and activities 2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. Moderate disability; requiring some help, but able to walk without assistance 4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. Dead |
| Incidence of parent artery thrombosis | through 365-day post procedure | — |
| Incidence of in-construct stenosis > 50% | through 365-day post procedure | — |
| Incidence of retreatment | through 180-day and 365-day post procedure | — |
| Incidence of peri-/post-procedural serious adverse events related to the device, procedure or antiplatelet therapy | through 180-day and 365-day post procedure | — |
| Incidence of complete angiographic occlusion without significant stenosis (≤ 50%), and no rebleeding or retreatment of the target aneurysm | through 365-day post procedure | — |
| Incidence of neurological death or disabling stroke | through 365-day post procedure | — |
| Pipeline™ Flex Device Deployment Success Rate | Day 0 During Procedure | — |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDavid Fiorella, MD
Stony Brook University Hospital
Outcome results
None listed